Literature DB >> 12368301

Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Laryssa Howe1, Caroline Leroux, Charles J Issel, Ronald C Montelaro.   

Abstract

Equine infectious anemia virus (EIAV) infection of horses is characterized by well-defined waves of viremia associated with the sequential evolution of distinct viral populations displaying extensive envelope gp90 variation; however, a correlation of in vivo envelope evolution with in vitro serum neutralization phenotype remains undefined. Therefore, the goal of the present study was to utilize a previously defined panel of natural variant EIAV envelope isolates from sequential febrile episodes to characterize the effects of envelope variation during persistent infection on viral neutralization phenotypes and to define the determinants of EIAV envelope neutralization specificity. To assess the neutralization phenotypes of the sequential EIAV envelope variants, we determined the sensitivity of five variant envelopes to neutralization by a longitudinal panel of immune serum from the source infected pony. The results indicated that the evolution of the EIAV envelope sequences observed during sequential febrile episodes produced an increasingly neutralization-resistant phenotype. To further define the envelope determinants of EIAV neutralization specificity, we examined the neutralization properties of a panel of chimeric envelope constructs derived from reciprocal envelope domain exchanges between selected neutralization-sensitive and neutralization-resistant envelope variants. These results indicated that the EIAV gp90 V3 and V4 domains individually conferred serum neutralization resistance while other envelope segments in addition to V3 and V4 were evidently required for conferring total serum neutralization sensitivity. These data clearly demonstrate for the first time the influence of sequential gp90 variation during persistent infection in increasing envelope neutralization resistance, identify the gp90 V3 and V4 domains as the principal determinants of antibody neutralization resistance, and indicate distinct complex cooperative envelope domain interactions in defining sensitivity to serum antibody neutralization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368301      PMCID: PMC136617          DOI: 10.1128/jvi.76.21.10588-10597.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).

Authors:  P M Rwambo; C J Issel; K A Hussain; R C Montelaro
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain.

Authors:  Y H Zheng; H Sentsui; T Nakaya; Y Kono; K Ikuta
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.

Authors:  J R Tschetter; K M Byrne; L E Perryman; T C McGuire
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

4.  Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Authors:  S A Hammond; S J Cook; D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse.

Authors:  Y H Zheng; T Nakaya; H Sentsui; M Kameoka; M Kishi; K Hagiwara; H Takahashi; Y Kono; K Ikuta
Journal:  J Gen Virol       Date:  1997-04       Impact factor: 3.891

6.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.

Authors:  D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies.

Authors:  J M Ball; K E Rushlow; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.

Authors:  R F Cook; S L Berger; K E Rushlow; J M McManus; S J Cook; S Harrold; M L Raabe; R C Montelaro; C J Issel
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses.

Authors:  D B Tumas; M T Hines; L E Perryman; W C Davis; T C McGuire
Journal:  J Gen Virol       Date:  1994-05       Impact factor: 3.891

View more
  18 in total

1.  Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.

Authors:  Wuwei Wu; Derek C Blythe; Hyelee Loyd; Robert H Mealey; Rebecca L Tallmadge; Karin S Dorman; Susan Carpenter
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

3.  Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.

Authors:  Xu Qi; Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Rongxian Shen; Fenglong Wang; Xiangang Kong; Zhiqiang Su; Jianhua Zhou
Journal:  Virus Genes       Date:  2010-06-05       Impact factor: 2.332

4.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.

Authors:  Jodi K Craigo; Corin Ezzelarab; Ronald C Montelaro
Journal:  J Virol Methods       Date:  2012-07-20       Impact factor: 2.014

6.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

7.  Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.

Authors:  Robert H Mealey; Amin Sharif; Shirley A Ellis; Matt H Littke; Steven R Leib; Travis C McGuire
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

8.  Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Authors:  Xiue Han; Ping Zhang; Wei Yu; Wenhua Xiang; Xiaodong Li
Journal:  Virus Genes       Date:  2016-08-29       Impact factor: 2.332

9.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.